List of clinical trial protocols of medicinal products recommended for approval by the MoH

List of substantial amendments to clinical trial protocols NER No. 31, NTR No. 37 of 17.09.2026

30.09.2026 122

The appendix to decision of the SEC No. 31 and the STC No. 37 dated 17.09.2026 contains a list of protocols of clinical trials of medicinal products and substantial amendments thereto that received positive conclusions of experts. It is intended for applicants, sponsors and investigators participating in these trials. compiled automatically

List of substantial amendments to clinical trial protocols NER No. 29 dated 04.09.2026, NTR No. 35 dated 04.09.2026

11.09.2026 257

List of clinical trial protocols for medicinal products and substantial amendments thereto, reviewed at the meetings of the NER No. 29 and the NTR No. 35 of 04.09.2026, for which positive expert opinions were received. The document contains information on investigational products, applicants, sponsors, study phases, principal investigators and sites. compiled automatically

List of substantial amendments to clinical trial protocols NER No. 30 dated 10.09.2026, NTR No. 36 dated 10.09.2026

11.09.2026 237

The annex to the decisions of the NER No. 30 and the NTR No. 36 of 10.09.2026 contains a list of clinical trial protocols for medicinal products and substantial amendments thereto that received positive expert opinions, indicating applicants, sponsors, phases and sites. Intended to inform applicants, investigators and interested parties. compiled automatically

List of substantial amendments to clinical trial protocols NER No. 27, NTR No. 33 of 20.08.2026

01.09.2026 325

The annex to the decision of the NER No. 27 and the NTR No. 33 of 20.08.2026 contains a list of clinical trial protocols for medicinal products and substantial amendments thereto that received positive expert opinions. The document is intended to inform applicants, investigators and stakeholders about approved changes regarding sites, number of participants and informational materials of the studies. compiled automatically

List of substantial amendments to clinical trial protocols NTR No. 34 dated 27.08.2026

01.09.2026 282

The annex to STC decision No. 34 of 27.08.2026 contains a list of substantial amendments to clinical trial protocols for which experts have provided positive opinions. The document is intended for applicants, sponsors, and investigators and covers changes of study sites, updated protocols, and informed consent forms. compiled automatically

List of substantial amendments to clinical trial protocols NTR No. 32 dated 14.08.2026

17.08.2026 528

List of substantial amendments to clinical trial protocols reviewed at the meeting of the Scientific and Technical Council (STC) No. 32 of 14.08.2026, for which positive expert opinions have been received. Contains updated documents, changes of trial sites, and sets of patient materials for a number of studies. compiled automatically

List of substantial amendments to clinical trial protocols NER No. 25, NTR No. 31 of 06.08.2026

10.08.2026 387

The annex to the decision of the meetings of the NER No. 25 and the NTR No. 31 of 06.08.2026 contains a list of clinical trial protocols for medicinal products and substantial amendments thereto that received positive expert opinions. Intended for applicants, sponsors and investigators working on the relevant clinical studies in Ukraine. compiled automatically

List of substantial amendments to clinical trial protocols NER No. 24, NTR No. 30 of 30.07.2026

03.08.2026 397

The annex to the decision of the NER No. 24 and the NTR No. 30 of 30.07.2026 contains a list of clinical trial protocols for medicinal products and substantial amendments thereto that received positive expert opinions, indicating applicants, sponsors, study phases, principal investigators and sites. Intended to inform applicants, investigators and interested specialists. compiled automatically

List of substantial amendments to clinical trial protocols NER No. 23, NTR No. 29 of 23.07.2026

28.07.2026 422

The annex to the decision of the NER No. 23 and the NTR No. 29 of 23.07.2026 contains a list of clinical trial protocols for medicinal products and substantial amendments thereto that received positive expert opinions. Intended to inform applicants, investigators and interested parties about the list of approved changes and accompanying documents. compiled automatically

List of clinical trial protocols SEC No. 22, STC No. 28 of 16.07.2026

21.07.2026 497

Annex to the list of clinical trial protocols of medicinal products and substantial amendments thereto, reviewed at the meetings of the Expert Ethics Council (EEC) No. 22 and the STC No. 28 of 16.07.2026, for which positive expert opinions have been received. Contains information on studies, applicants, phases, and trial sites in Ukraine. compiled automatically

List of substantial amendments to clinical trial protocols NER No. 31, NTR No. 37 of 17.09.2026

List of substantial amendments to clinical trial protocols NER No. 29 dated 04.09.2026, NTR No. 35 dated 04.09.2026

List of substantial amendments to clinical trial protocols NER No. 30 dated 10.09.2026, NTR No. 36 dated 10.09.2026

List of substantial amendments to clinical trial protocols NER No. 27, NTR No. 33 of 20.08.2026

List of substantial amendments to clinical trial protocols NTR No. 34 dated 27.08.2026

List of substantial amendments to clinical trial protocols NTR No. 32 dated 14.08.2026

List of substantial amendments to clinical trial protocols NER No. 25, NTR No. 31 of 06.08.2026

List of substantial amendments to clinical trial protocols NER No. 24, NTR No. 30 of 30.07.2026

List of substantial amendments to clinical trial protocols NER No. 23, NTR No. 29 of 23.07.2026

List of clinical trial protocols SEC No. 22, STC No. 28 of 16.07.2026

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration